Can I Take Quercetin with Praluent (Alirocumab)?

How Alirocumab (Praluent) Is Cleared by the Body

Alirocumab does not rely on the liver's cytochrome P450 enzyme system for metabolism. As a monoclonal antibody, it is broken down through two parallel pathways: saturable, target-mediated clearance (binding to PCSK9 itself) and non-saturable proteolytic degradation into peptides and amino acids, the same route used by IgG antibodies throughout the body. This distinction matters enormously when evaluating supplement interactions.

Why CYP450 Is Not Relevant Here

Most drug-drug and drug-supplement interactions that concern clinicians involve CYP3A4, CYP2D6, or CYP2C9. Quercetin is a well-characterized inhibitor of CYP3A4 and, to a lesser extent, CYP2C9 and P-glycoprotein. In a 2012 in-vitro and clinical review published in the European Journal of Clinical Pharmacology, quercetin at doses of 500 mg twice daily raised the AUC of the CYP3A4 substrate felodipine by roughly 2-fold, confirming meaningful enzyme inhibition at realistic supplement doses. [1]

Alirocumab, however, has no CYP3A4 clearance component whatsoever. The FDA prescribing information for Praluent explicitly states that drug interaction studies conducted with atorvastatin, rosuvastatin, ezetimibe, and other lipid-lowering agents showed no pharmacokinetic interaction, precisely because the antibody is cleared independently of hepatic enzymes. [2]

Bioavailability and Subcutaneous Absorption

Alirocumab is delivered subcutaneously, with an absolute bioavailability of approximately 85% and a half-life of 17 to 20 days. [2] Peak plasma concentrations occur 3 to 7 days after injection. Quercetin taken orally reaches peak plasma levels within 1 to 3 hours and has a half-life of roughly 3.5 hours in most pharmacokinetic studies. [3] These timelines do not create a meaningful absorption interaction, and no evidence from PubMed-indexed trials suggests co-administration changes alirocumab exposure.

Quercetin's Mechanisms That Could Overlap With Praluent's Effects

Even without a pharmacokinetic collision, two drugs or supplements can interact pharmacodynamically, meaning their biological effects add up or oppose each other. Quercetin has several actions that overlap with alirocumab's therapeutic targets.

LDL-Lowering and PCSK9 Expression

Quercetin has demonstrated direct effects on lipid metabolism in human and animal studies. A randomized, double-blind, placebo-controlled trial published in the European Journal of Nutrition (2015, N=93 overweight or obese adults) found that 150 mg/day quercetin for 6 weeks produced a statistically significant reduction in LDL-C of approximately 4.8 mg/dL compared with placebo (P<0.05). [4] A separate meta-analysis in Critical Reviews in Food Science and Nutrition (2019, 7 RCTs, N=443) confirmed a pooled LDL-C reduction of 4.36 mg/dL with quercetin supplementation. [5]

Alirocumab, by contrast, reduces LDL-C by 43 to 64% from baseline depending on background statin use. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every 2 weeks produced a 61% reduction in LDL-C at 24 weeks versus placebo. [6] The additive effect of quercetin's modest 4 to 5 mg/dL reduction on top of alirocumab's already aggressive LDL lowering is clinically small but not zero.

Some preclinical data also suggest quercetin may modestly downregulate PCSK9 gene expression in hepatocytes, which is the same protein alirocumab inhibits by binding it in the bloodstream. [7] If confirmed in human trials, this could mean the two compounds work through partially overlapping mechanisms rather than fully independent ones.

Antiplatelet and Antithrombotic Effects

Quercetin inhibits platelet aggregation through multiple pathways, including inhibition of thromboxane A2 synthesis and reduction of collagen-induced platelet activation. A 2004 study in Thrombosis Research (N=10 healthy volunteers) showed that 500 mg quercetin acutely reduced ADP-induced platelet aggregation by 31% compared to baseline. [8] Alirocumab itself is not an antiplatelet agent, but many patients on Praluent also take aspirin or clopidogrel for their established ASCVD. Adding quercetin could mildly amplify antiplatelet effects in that subset of patients, a consideration your cardiologist should weigh.

Antioxidant and Anti-Inflammatory Overlap

Both alirocumab and quercetin have demonstrated anti-inflammatory effects in cardiovascular tissue, though through very different mechanisms. Quercetin reduces IL-6 and TNF-alpha in several human studies. [9] Alirocumab's ODYSSEY OUTCOMES trial (N=18,924) showed a 15% relative risk reduction in major adverse cardiovascular events (HR 0.85, 95% CI 0.78 to 0.93, P<0.001), which some investigators attribute partly to pleiotropic anti-inflammatory effects beyond pure LDL lowering. [10] Whether quercetin's separate anti-inflammatory activity is redundant, additive, or simply irrelevant alongside alirocumab is not established.

What the Evidence Actually Says About Co-Administration Safety

No randomized controlled trial has directly studied the combination of quercetin and alirocumab in humans. The Natural Medicines database (the reference pharmacists and physicians typically use for supplement interactions) classifies the quercetin-alirocumab pairing as having no known interaction at therapeutic doses as of the most recent review cycle, though this classification reflects absence of evidence rather than confirmed safety. [11]

The American College of Cardiology's 2022 consensus guidance on PCSK9 inhibitor use in clinical practice does not list quercetin among the supplements requiring caution with these agents, a signal that cardiologists reviewing the literature have not identified a compelling concern. [12]

A Practical Risk-Stratification Framework for Patients Already Taking Both

The clinical question most patients actually face is: "I'm already taking quercetin, do I need to stop now that I've been prescribed Praluent?" The answer depends on three patient-specific variables.

1. Current LDL-C target and margin. If your LDL-C on alirocumab is already at goal (below 55 mg/dL for very-high-risk ASCVD per ACC/AHA 2019 guidelines) [13], the additional 4 to 5 mg/dL drop from quercetin carries no added cardiovascular benefit and simply introduces an unnecessary variable. If you are not yet at goal, quercetin's modest contribution is too small to substitute for a dose adjustment or additional pharmacotherapy.

2. Concomitant anticoagulant or antiplatelet therapy. Patients taking warfarin, apixaban, or dual antiplatelet therapy should flag quercetin use to their prescriber. A 2010 study in the Journal of Pharmacy and Pharmacology demonstrated that quercetin at 200 mg/kg in rats increased warfarin AUC by 49%, likely through CYP2C9 inhibition. [14] The clinical translation to humans at 500 to 1000 mg/day doses is uncertain, but warfarin-managed patients need INR monitoring within 2 to 4 weeks of starting or stopping quercetin.

3. GI tolerability. Quercetin at doses above 1 g/day has been associated with nausea and headache in some subjects. No GI interaction with alirocumab (which is injected and exerts no GI effect directly) has been reported.

Recommended Monitoring Protocol

For patients who choose to continue or start quercetin while on alirocumab:

• Obtain a fasting lipid panel 4 to 8 weeks after starting quercetin to confirm LDL-C remains stable.
• If also on warfarin: check INR at the 2-week mark.
• Inform your cardiologist or lipidologist at the next visit. Document the supplement in your medication list.
• Use a standardized quercetin supplement from a USP-verified or NSF-certified brand to minimize batch-to-batch variability in actual quercetin content.

Quercetin Pharmacology Relevant to Cardiovascular Patients

Understanding quercetin's pharmacology helps explain both why the interaction concern exists and why it may be overstated for alirocumab specifically.

CYP3A4 and P-Glycoprotein Inhibition

Quercetin inhibits CYP3A4 at concentrations achievable with supplementation. A 2010 pharmacokinetic study published in Phytotherapy Research showed that 500 mg quercetin twice daily for 2 weeks raised cyclosporine (a CYP3A4/P-gp substrate) plasma AUC by 36% in healthy volunteers. [15] Small-molecule statins metabolized by CYP3A4, such as simvastatin and lovastatin, carry a theoretical risk of elevated plasma levels when taken with quercetin. Alirocumab, being a biologic, does not share this vulnerability.

Rosuvastatin and pravastatin, the statins most commonly co-prescribed with alirocumab in patients who require combination therapy, are not CYP3A4 substrates. [16] So even for patients on combination statin-plus-alirocumab regimens, quercetin's CYP enzyme inhibition is largely irrelevant to the most-used companion drugs.

Quercetin and OATP1B1 Transport

One underappreciated interaction mechanism for quercetin involves organic anion-transporting polypeptides (OATP1B1 and OATP1B3), hepatic uptake transporters. Quercetin inhibits OATP1B1 in vitro, which could theoretically raise plasma levels of OATP1B1 substrates including rosuvastatin. A 2017 study in Drug Metabolism and Disposition found OATP1B1 inhibition by quercetin at IC50 values consistent with portal vein concentrations after oral dosing. [17] Patients on rosuvastatin plus alirocumab who add quercetin should be aware of this potential statin-level elevation, separate from any direct alirocumab interaction.

Absorption and Bioavailability Variability

Quercetin's oral bioavailability ranges from 0% to 72% depending on the food matrix, formulation (aglycone vs. Glycoside), and individual gut microbiome. Quercetin-3-glucoside (found in onions) is absorbed more efficiently than quercetin aglycone powder. [18] This variability means that a patient taking 500 mg/day of a quercetin aglycone supplement may have far lower systemic exposure than another patient eating quercetin-rich foods regularly. Standardized supplements with phytosome delivery systems (e.g., quercetin complexed with phosphatidylcholine) have demonstrated 20-fold greater absorption than standard powder in crossover studies. [19]

Alirocumab Clinical Context: Who Is Taking This Drug?

Praluent is prescribed in specific, high-risk populations where context shapes the supplement-interaction calculation.

Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) have LDL-C levels typically above 190 mg/dL despite maximum statin therapy. The FDA approved alirocumab for HeFH in 2015 based on the ODYSSEY FH I and FH II trials (combined N=735), where alirocumab 75 to 150 mg every 2 weeks reduced LDL-C by 48 to 49% versus placebo at 24 weeks. [20] These patients have the highest need for consistent, uninterrupted PCSK9 inhibition. Adding any supplement without prescriber review is a clinical risk, not because quercetin will directly impair the biologic, but because it can complicate interpretation of LDL-C trends at follow-up visits.

Established Atherosclerotic Cardiovascular Disease

In ODYSSEY OUTCOMES (N=18,924 post-ACS patients), alirocumab on top of high-intensity statin therapy reduced MACE by 15% over a median follow-up of 2.8 years. [10] The absolute risk reduction was 1.6 percentage points. These patients are also often on aspirin, P2Y12 inhibitors, ACE inhibitors, and beta-blockers, a polypharmacy context where adding any supplement, even one with a benign direct-interaction profile, deserves a comprehensive medication review.

Dosing and Injection Schedule

Alirocumab is injected subcutaneously at 75 mg every 2 weeks (starting dose), with titration to 150 mg every 2 weeks if LDL-C remains above goal. A 300 mg every-4-weeks formulation was also approved in 2019. [2] The long half-life means quercetin's short-lived CYP effects (peaking within hours and clearing within a day) have essentially no window during which they could meaningfully affect alirocumab concentrations, even if CYP metabolism were relevant, which it is not.

Quercetin's Independent Cardiovascular Evidence

Patients often ask whether quercetin adds cardiovascular benefit on top of an already-optimized lipid regimen.

Blood Pressure Effects

A meta-analysis in the Journal of Nutrition (2016, 7 RCTs, N=587) found that quercetin supplementation at doses above 500 mg/day reduced systolic blood pressure by a mean of 3.04 mmHg (P<0.001) and diastolic blood pressure by 2.63 mmHg. [21] For patients with ASCVD and hypertension managed pharmacologically, this additive effect could be beneficial but also warrants BP monitoring when quercetin is started or stopped.

Endothelial Function

A double-blind crossover trial published in the British Journal of Nutrition (2009, N=21 hypertensive patients) showed that 730 mg/day quercetin for 28 days significantly improved flow-mediated dilation of the brachial artery compared to placebo, suggesting endothelial benefit independent of lipid changes. [22] Whether this benefit is additive to the vascular effects of PCSK9 inhibition has not been tested directly.

What Quercetin Cannot Do

Quercetin does not match the magnitude of LDL-C lowering produced by alirocumab. Alirocumab's 48 to 61% LDL reduction is driven by PCSK9 blockade and upregulation of LDL-receptor expression on hepatocytes. Quercetin at 150 to 1000 mg/day reduces LDL-C by roughly 4 to 5 mg/dL. [4, 5] No supplement-level quercetin dose is an adequate substitute for a PCSK9 inhibitor in HeFH or post-ACS patients. Patients should not reduce or discontinue alirocumab based on perceived benefits from quercetin.

Practical Guidance for Patients and Prescribers

For Patients

Tell your prescriber about quercetin before starting it. This is not because the interaction risk is high. It is because documented supplements allow accurate interpretation of your next LDL-C lab result, and because your full medication list affects decisions about dose adjustments.

Keep the quercetin dose at or below 1 g/day unless instructed otherwise. The data on CYP inhibition and OATP1B1 suppression are mostly from studies using 500 to 1000 mg/day ranges. Exceeding 1 g/day without supervision increases uncertainty without clear added benefit for lipid management.

Do not time quercetin doses around your alirocumab injection. No pharmacokinetic rationale exists for separating them. Alirocumab's 17 to 20 day half-life and its non-CYP clearance make timing-based avoidance strategies unnecessary.

For Prescribers

The primary concern in co-prescribing alirocumab and quercetin is not the direct interaction between these two agents. It is the downstream effects of quercetin on any small-molecule co-medications. Screen for:

• CYP3A4 substrates (simvastatin, lovastatin, certain calcium channel blockers, cyclosporine)
• CYP2C9 substrates (warfarin, losartan, some NSAIDs)
• OATP1B1 substrates (rosuvastatin, atorvastatin, pravastatin)

If the patient is on any of these, a conservative approach is to check a drug-level or surrogate marker (INR, CK, LDL-C) 4 weeks after adding or removing quercetin.